Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases. We create distinct and transformative treatments for endocrine diseases where there is a significant unmet medical need.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
November 9, 2020
Millendo Therapeutics Reports Third Quarter 2020 Operating and Financial Results
September 24, 2020
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
110 Miller Avenue, Suite 100
Ann Arbor, MI 48104
734-845-9000
millendo@millendo.com
Millendo Therapeutics SAS
c/o Canopee consulting
8 rue Berjon
69009 Lyon
France
Tel +33 472 18 94 28